Navigation Links
Stem Cell Transplantation Program at Hackensack University Medical Center: First in Nation to Receive Joint Commission Certification for Quality and First in New Jersey to be Named a Blue Distinction(R) Center for Specialty Care.
Date:10/2/2008

HACKENSACK, N.J., Oct. 2 /PRNewswire/ -- The Blood and Marrow Stem Cell Transplantation Program at the John Theurer Cancer Center at Hackensack University Medical Center is the first in the United States to receive Disease Specific Care Certification for stem cell transplantation from The Joint Commission, the nation's leading accrediting agency for hospitals and healthcare organizations. The Blood and Marrow Transplantation Program also recently became the first and only program in New Jersey to be named a Blue Distinction(R) Center for Specialty Care by the nationwide Blue Cross and Blue Shield companies.

Both of these designations attest to the high quality of the program's clinical services, the expertise of its faculty and staff, stringent quality indicators that are maintained, research studies that are under way, and a rigorous quest for continuous improvement. The Blood and Marrow Stem Cell Transplantation Program is one of the 10 largest in the United States. Nearly 300 adults and children throughout the country with cancer and serious blood disorders come to the John Theurer Cancer Center each year to undergo a life-saving stem cell transplant at the program. Last year, the program reported outcomes success rates of more than 95 percent for the procedure.

"These designations attest to the high level of expertise offered by our Blood and Marrow Stem Cell Transplantation Program's chief, Dr. Scott Rowley, by his associate, Dr. Michele Donato, and by the entire transplantation team," says Andrew L. Pecora, M.D., chairman and executive administrative director of the John Theurer Cancer Center at Hackensack University Medical Center.

The Blood and Marrow Stem Cell Transplantation Program received Disease Specific Certification after a rigorous on-site, unannounced, day-long evaluation on August 29 that assessed clinical practices, policies and procedures, and performance measurement requirements. Four specific program measures were monitored, including discharge criteria, survival at 100 days, acute graft-versus-host disease documentation, and donor follow-up. The reviewer evaluated the program's adherence to the clinical standards of the Foundation for the Accreditation of Cellular Therapy.

The Blue Distinction(R) Center for Specialty Care designation is awarded by the BC/BS companies to medical facilities that have demonstrated experience in delivering quality healthcare. The Blood and Marrow Stem Cell Transplantation Program is one of 70 Blue Distinction(R) Centers for Transplants nationwide, but the only one in New Jersey. The designation is based on evidence-based selection criteria established with leading medical specialists and societies, including the Center for International Blood and Marrow Transplant Research and the Foundation for the Accreditation of Cellular Therapy. In achieving the Blue Distinction(R) Center designation, the program was evaluated on volume of cases, survival, a stable team of transplantation experts and subspecialists, the facility, data management, patient management plans, post-operative phase, patient education, policies and procedures, quality management, and patient satisfaction review process.

The John Theurer Cancer Center's Blood and Marrow Stem Cell Transplantation Program is the only one in New Jersey that is approved by the National Marrow Donor Program to perform all types of transplants: autologous (using the patient's own stem cells), allogeneic (using a donor's stem cells), and umbilical cord (using stem cells collected from umbilical cords). Many of the advances in stem cell transplantation techniques used today were developed here. There are currently more than 50 clinical trials under way at the program.

The John Theurer Cancer Center provides extraordinary cancer care by offering multidisciplinary care, personalized treatment, innovative research, superior outcomes, and patient satisfaction within 14 disease-specific divisions. For more information, call 201-996-5900 or visit humc.com.

Available Topic Experts: For information on the listed expert(s), click appropriate link.

Scott Rowley, M.D |. https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=78490

Michele L. Donato, M.D. | https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=79128


'/>"/>
SOURCE John Theurer Cancer Center
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The First Ever Transplantation World-Wide of Entire Arms at the "Klinikum rechts der Isar" in Munich
2. Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop Designer Transplants
3. Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkins Lymphoma
4. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
6. UCB Scholarship Program Awards $300,000 to Students Living with Crohns Disease
7. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
8. KGI Offers Mammalian Cell Culture Program for Biotech Industry Professionals
9. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
10. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
11. 2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expos 14-Year History
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
Breaking Biology Technology:
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
(Date:3/21/2016)... 22, 2016 Unique technology ... for superior security   Xura, ... of secure digital communications services, today announced it is ... offer enterprise customers, particularly those in the Financial Services ... voice authentication within a mobile app, alongside, and in ...
Breaking Biology News(10 mins):